Immunogenicity of pembrolizumab in patients with advanced tumors

BACKGROUND: Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clea...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vugt, Marianne J. H., Stone, Julie A., De Greef, “Rik” H. J. M. M., Snyder, Ellen S., Lipka, Leslie, Turner, David C., Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H., Kondic, Anna G., De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686242/
https://www.ncbi.nlm.nih.gov/pubmed/31395089
http://dx.doi.org/10.1186/s40425-019-0663-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686242/
https://www.ncbi.nlm.nih.gov/pubmed/31395089
http://dx.doi.org/10.1186/s40425-019-0663-4

Ejemplares similares